U.S. markets close in 5 hours 10 minutes
  • S&P 500

    4,402.73
    +1.27 (+0.03%)
     
  • Dow 30

    35,009.47
    -49.05 (-0.14%)
     
  • Nasdaq

    14,746.44
    +85.86 (+0.59%)
     
  • Russell 2000

    2,192.43
    +0.60 (+0.03%)
     
  • Crude Oil

    71.82
    +0.17 (+0.24%)
     
  • Gold

    1,797.00
    -2.80 (-0.16%)
     
  • Silver

    24.91
    +0.26 (+1.04%)
     
  • EUR/USD

    1.1801
    -0.0025 (-0.21%)
     
  • 10-Yr Bond

    1.2590
    +0.0250 (+2.03%)
     
  • GBP/USD

    1.3874
    -0.0005 (-0.03%)
     
  • USD/JPY

    110.1040
    +0.3370 (+0.31%)
     
  • BTC-USD

    39,680.91
    +1,581.97 (+4.15%)
     
  • CMC Crypto 200

    930.03
    +0.10 (+0.01%)
     
  • FTSE 100

    7,015.13
    +19.05 (+0.27%)
     
  • Nikkei 225

    27,581.66
    -388.56 (-1.39%)
     

Pfizer's breast cancer drug combo falls short of survival goal

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) - Pfizer Inc (PFE.N) said on Monday a combination of its breast cancer drug, Ibrance, and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial.

Ibrance is Pfizer's blockbuster treatment and is already approved as a combination with endocrine therapy for use in breast cancer patients. The treatment brought in sales of $933 million in the first quarter of 2018.

Pfizer said on Monday the results demonstrated a positive trend in a ratio that helps determine to what extent a treatment can shorten the duration of an illness, but failed to reach statistical significance.

An interim analysis of the trial in 2015 showed that the Ibrance combo had met its main goal of progression-free survival, or extending the length of time a patient lives without the disease worsening.

The company would present detailed data on the trial at an upcoming meeting.

(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)